We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+32.61%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$439M
AUM Growth
+$21.9M
Cap. Flow
-$50M
Cap. Flow %
-11.37%
Top 10 Hldgs %
49.48%
Holding
86
New
10
Increased
12
Reduced
30
Closed
14

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$4.87M
2
PODD icon
Insulet
PODD
+$2.97M
3
KALV
KalVista Pharmaceuticals
KALV
+$2.75M
4
CATX icon
Perspective Therapeutics
CATX
+$2.65M
5
LRMR icon
Larimar Therapeutics
LRMR
+$2.59M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15.2M
2
IMGN
Immunogen Inc
IMGN
+$5.74M
3
SAGE
Sage Therapeutics
SAGE
+$5.31M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.25M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
76
MacroGenics
MGNX
$257M
– –
-152,250
Closed -$1.46M
MREO
77
Mereo BioPharma
MREO
$47.3M
– –
-778,813
Closed -$1.8M
ORIC icon
78
Oric Pharmaceuticals
ORIC
$1.4B
– –
-72,797
Closed -$670K
SAGE
79
DELISTED
Sage Therapeutics
SAGE
– –
-245,000
Closed -$5.31M
VTGN icon
80
VistaGen Therapeutics
VTGN
$12.8M
– –
-41,886
Closed -$215K
SPRB
81
Spruce Biosciences
SPRB
$129M
– –
-7,313
Closed -$1.61M
KNTE
82
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-50,000
Closed -$119K
KRTX
83
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-48,145
Closed -$15.2M
IMGN
84
DELISTED
Immunogen Inc
IMGN
– –
-193,661
Closed -$5.74M
MRTX
85
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-89,387
Closed -$5.25M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, DAFNA Capital Management held 86 positions worth $439M, up 5.3% from $417M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management withdrew a net $50M in Q1 2024, closing 14 positions and reducing 30 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Insulet worth $2.73M.

  • DAFNA Capital Management's largest Q1 2024 buy was Insulet: 15,900 shares worth $2.73M.
  • DAFNA Capital Management added most to AtriCure in Q1 2024, an estimated $4.87M increase.
  • DAFNA Capital Management's biggest Q1 2024 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.9M.
  • DAFNA Capital Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $15.2M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $439M portfolio in Q1 2024.
  • DAFNA Capital Management opened 10 new positions and closed 14 in Q1 2024.
  • DAFNA Capital Management's portfolio value rose 5.3% quarter-over-quarter to $439M.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.